Comparison of the Metabolic Effects of Ritonavir-Boosted Darunavir or Atazanavir Versus Raltegravir, and the Impact of Ritonavir Plasma Exposure: ACTG 5257
Clin Infect Dis June 15, 2015 V.60 N.12 P.1842-1851
Ighovwerha Ofotokun, Lumine H. Na, Raphael J. Landovitz, Heather J. Ribaudo, Grace A. McComsey, Catherine Godfrey, Francesca Aweeka, Susan E. Cohn, Manish Sagar, Daniel R. Kuritzkes, Todd T. Brown, Kristine B. Patterson, Michael F. Para, Randi Y. Leavitt, Angelina Villasis-Keever, Bryan P. Baugh, Jeffrey L. Lennox, and Judith S. Currier for the AIDS Clinical Trials Group (ACTG) A5257 Team
In this randomized trial, raltegravir had more of a favorable lipid profile than ritonavir-boosted atazanavir or ritonavir-boosted darunavir–based regimens.
Metabolic syndrome rates increased to the same degree for all 3 regimens.
There was no relationship between ritonavir exposure and lipid levels.